Evidence map›Paper›PMID 39733162›Full record

ArticleScientific reports2024

405 nm violet-blue light inactivates hepatitis C cell culture virus (HCVcc) in ex vivo human platelet concentrates and plasma.

Joseph W Jackson, Pravin R Kaldhone, Caitlin Stewart, John Anderson, Scott MacGregor, Michelle Maclean, Marian Major, Chintamani D Atreya

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Joseph W Jackson *Division of Blood Components and Devices, Center for Biologics Evaluation and Research, FDA, Silver Spring, MD, 20993, USA.
Pravin R Kaldhone *Division of Blood Components and Devices, Center for Biologics Evaluation and Research, FDA, Silver Spring, MD, 20993, USA.
Caitlin StewartDepartment of Electronic and Electrical Engineering, The Robertson Trust Laboratory for Electronic Sterilization Technologies (ROLEST), University of Strathclyde, Glasgow, UK.
John AndersonDepartment of Electronic and Electrical Engineering, The Robertson Trust Laboratory for Electronic Sterilization Technologies (ROLEST), University of Strathclyde, Glasgow, UK.
Scott MacGregorDepartment of Electronic and Electrical Engineering, The Robertson Trust Laboratory for Electronic Sterilization Technologies (ROLEST), University of Strathclyde, Glasgow, UK.
Michelle MacleanDepartment of Electronic and Electrical Engineering, The Robertson Trust Laboratory for Electronic Sterilization Technologies (ROLEST), University of Strathclyde, Glasgow, UK.
Marian MajorDivision of Viral Products, Center for Biologics Evaluation and Research, FDA, Silver Spring, MD, 20993, USA. marian.major@fda.hhs.gov.
Chintamani D AtreyaDivision of Blood Components and Devices, Center for Biologics Evaluation and Research, FDA, Silver Spring, MD, 20993, USA. chintamani.atreya@fda.hhs.gov.

Funding

FDA Intramural Fund Z01 BK 04010-11 LHVFDA Intramural Fund Z01 BQ 02020-15 LCH
6 · The paper itself

Abstract

Added safety measures coupled with the development and use of pathogen reduction technologies (PRT) significantly reduces the risk of transfusion-transmitted infections (TTIs) from blood products. Current approved PRTs utilize chemical and/or UV-light based inactivation methods. While the effectiveness of these PRTs in reducing pathogens are well documented, these can cause tolerable yet unintended consequences on the quality and efficacy of the transfusion products. As an alternative to UV-based approaches, we have previously demonstrated that 405 nm violet-blue light exposure successfully inactivates a variety of pathogens, including bacteria, parasites, and viruses, in both platelet concentrates (PCs) and plasma. Herein, we show that 405 nm light treatment effectively inactivates hepatitis C cell culture virus (HCVcc) by up to ~ 3.8 log10 in small volumes of a variety of matrices, such as cell culture media, PBS, plasma, and PCs with 27 J/cm

Indexed as

Blood PlateletsHepacivirusLightVirus InactivationBlue LightHepatitis CHumansPlasma405 nm lightblue lightHCVPathogen inactivationPlasmaPlatelets

Identifiers

PMID39733162
PMCPMC11682286

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.